Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort

Eiichi Tanaka; Eisuke Inoue; Mai Abe; Kumiko Saka; Eri Sugano; Moeko Ochiai; Rei Yamaguchi; Katsunori Ikari; Hisashi Yamanaka; Masayoshi Harigai

doi:10.1093/mr/roab120

Changes in treatment adherence and behaviour during the COVID-19 pandemic in Japanese patients with rheumatoid arthritis: Results from cross-sectional study in the IORRA cohort

Mod Rheumatol. 2022 Oct 15;32(6):1193-1195. doi: 10.1093/mr/roab120.

Authors

Eiichi Tanaka^{1

2}, Eisuke Inoue^{1

3}, Mai Abe^{1

2}, Kumiko Saka^{1

2}, Eri Sugano^{1

2}, Moeko Ochiai^{1

2}, Rei Yamaguchi^{1

2}, Katsunori Ikari^{2

4

5}, Hisashi Yamanaka^{1

6

7}, Masayoshi Harigai^{1

2}

Affiliations

¹ Department of Internal Medicine, Division of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
² Institute of Rheumatology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
³ Research Administration Center, Showa University, Tokyo, Japan.
⁴ Division of Multidisciplinary Management of Rheumatic Diseases, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
⁵ Department of Orthopedic Surgery, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
⁶ Rheumatology, Sanno Medical Center, Tokyo, Japan.
⁷ Department of Rheumatology, International University of Health and Welfare, Tokyo, Japan.

No abstract available

Keywords: COVID-19; adherence; biological disease-modifying antirheumatic drugs; methotrexate; pandemic; rheumatoid arthritis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Rheumatoid* / drug therapy
Arthritis, Rheumatoid* / epidemiology
COVID-19*
Cross-Sectional Studies
Humans
Japan / epidemiology
Methotrexate / therapeutic use
Pandemics
Treatment Adherence and Compliance

Substances

Antirheumatic Agents
Methotrexate

Publication types

MeSH terms

Substances

Grants and funding